CA2111603A1 - Stable antibody solution and stabilization of antibody - Google Patents
Stable antibody solution and stabilization of antibodyInfo
- Publication number
- CA2111603A1 CA2111603A1 CA002111603A CA2111603A CA2111603A1 CA 2111603 A1 CA2111603 A1 CA 2111603A1 CA 002111603 A CA002111603 A CA 002111603A CA 2111603 A CA2111603 A CA 2111603A CA 2111603 A1 CA2111603 A1 CA 2111603A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- solution
- direct
- labelled
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Abstract
ABSTRACT OF THE DISCLOSURE
An antibody solution containing (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure and a method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody are disclosed.
An antibody solution containing (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure and a method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody are disclosed.
Description
2 ~ 3 STABLE ANTIBO~Y SOL~TION AND STABILIZATIO~I OF ~NTIBODY
FIELD OF THE INVENTION
This invention relates to a stable antibody or labelled antibody solution and to a method for stabilizing an antibody or a labelled antibody.
BACKGROUND OF THE INVENTION
A number of diagnostic reagents using an antibody or a labelled an~ibody have recently been developed. In particular, a monoclonal antibody has been ste~dily ex~ending its utility in the field of diagnosis and therapeutic drugs hecause of its high reaction specificity.
Many of antibodies, especially monoclonal antibodies composed of a single protein, have a unique character, which has made it difficult to obtain a stable solution thereof.
Similarly to general enzyme proteins, methods of preserving antibodies include freezing, lyophilization and ammonium sulfate fractionation followed by suspension. However, these methods not only involve complicated steps not easy to carry out but require much labor for preparing an anti~ody solution from the preserved state on use.
Studies have thus been given to a method for preserving an antibody in the form of a solution. Proposals so far made for obtainin~ an antibody solution include a method of adding albumin (WO 92/01808 corresponding to EP--A-0 539 584) and a method of adding hydrolyzed egg albumin ~P-A-61~76423 corresponding to U.S. Paten-t 4,650,772 and EP~A~0 - ~-... :
,;, . .
170 983, the term ~'JP-A~' as used herein means an "unexamined published Japanese patent application"). These methods, however, are still unsatisfactory for preparing a stabilized antibody solution.
SUMI~ARY OF THE INVENTION
An object of th0 present invention is to provide a stable antibody solution.
Another object of the present invention is to provide a method for stabilizing an antibody.
As a result of extensive investigations, the present inventors have found that addition of a specific azo dye which has no stabilizing effect when used alone to an antibody solution containing albumin surprisingly brings about a marked improvement in antibody stability. The present invention has been completed based on this finding.
The present invention provides an antibody solution containing (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure.
The present invention also provides a method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody.
, :
... ~ .:.:
~ .
2 ~ 0 3 DETAILED DESCRIPTION OF THE INVENTION
The antibody which can be stabilized according to the present invention is not particularly limited in kind and concentration, etc., and may be selected appropriately depending on the use. If desired, the antibody selected may be labelled with, for examp7e, fluorescent substance, such as fluorescein or rhodamine; biotin; enzyme, such as peroxidase or alkaline phosphatase; radioactive substance, such as l25I
and the like.
The concentration of the antibody in the antibody solution of the present invention varies depending on the type of the antibody. For example, anti-MYcoPlasma Pneumonia monoclonal antibody Gl-E6 is contained in a concentration ranging from 10 to 200 ~g/mQ.
Albumin which can be us~d in the present invention includes bovine serum albumin, human albumin~ ovalbumin, lactalbumin, etc. Since monoclonal antibodies are composed of a single protein unlike a polyclonal antibody obtained from antiserum, they mostly have a sp2cific character and their stability varies depending on the kind. Accordingly, where the antibody to be stabilized is a monoclonal antibody, it is desirable to select one or more kinds of albumin species according to the kind of the antibody. The albumin is used in an amount effective to stabilize the antibody, preferably in a concentration ranging from 1 to 20 mg/mQ in the antibody solution, though varying depending on the kind of the antibody.
- .
`",-:
.,. ~ , j,:. . .~ : . ~
6~3 The azo dye containing naphthalenesulfonic acid in its structure includes, for example, Direct Green 1, Direct Green 6, Direct Green 59, Direct Black 4, Direct BlacX 22, Direct Black 38, Direct Blue 1, Direct Blue 6, Direct Blue 53 (Evan's Blue), Direct Red 2, Direct Red 28 (Congo Red), and Direct Red 79, etc.
Although these azo dyes make no contribution to stabilization of an antibody when used alone, they exhibit a high stabilizing activity when combined with albumin. While varying depending on the kind of the antibody used, the azo dye is added in an amount effective to enhance antibody-stabilizing ability of albumin, preferably in a concentration ranging from 1 to 100 ~q/mQ in the antibody solution.
Usually, one kind of azo dyes would be sufficient. If necessary, two or more kinds of azo dyes may be used at an appropriate ratio.
A buffer solution having a neutral pH value can be used as a solution to which the components are added.
Examples of the buffer solutions include physiological saline, phosphate buffer, Tris-hydrochloride buffer, HEPES
buffer and the like. The pH value of the antibody solution is adjusted to 5 to 9, preferably 6 to 8, though it varies depending on the type of the antibody.
If desired, the antibody solution according to the present invention may urther contain antiseptics or preservatives, such as sodium azide and the like.
:: :
2~
The antibody solution of the present invention can be prepared by mixing the above-mentioned essential components (1) to (3) in a usual manner. For example, an antibody is dissolved in a solution containing 1 to 20 mg/mQ of albumin, and an azo dye is then added thereto in a concentration of from 1 to 100 ~g/m~. It is also possible to mix an antibody solution with a separatel~ prepared solution containing the o~her components. The order of addition of components (1) to (3) is not xestricted. Thereafter, if desired, an antiseptic, a preservative or any other additives may be added and dissolved oxygen may be removed from the solution.
The resulting solution may be then put into a light-shielding container to provide a final product of a stable antibody solution.
The antibody solution of the present invention can be used as a diagnosing reagent, a reagent for detecting various antigens and the like.
According to the present invention, an antibody can be preserved stably in the form of a solu~ion which is convenient for use.
The present invention will now be illustrated in greater detail with reference to Examples and Test Examples, but the present invention should not be construed as beiny limited thereto. Monoclonal antibodies used in Examples are ~s follows.
-2 i ~ 3 Gl-E6:
Disclosed in JP-A-63-184064.
C2H5-C10 and 3-19-11:
Separately prepared by the same method as disclosed in JP-A-63-184064.
Anti-Candida albicans protease monoclonal antibody (IqG):
A mouse (Balb/c, female) ~as immunized with acidic protease of a pathogenic yeast, Candida albicans (see F.
Macdnald and F.C. Odds, J. Med. Microbiol., Vol. 13, pp. 423-435 (1980)3 together with complete Freund's adjuvant. After a booster shot, spleen cells of the animal and myeloma cells (X63-Ag8.6.5.3) were fused together with the aid of polyethylene glycol according to the process described in JP-A-~3-184064. The resulting monoclonal antibody-producing hybridoma was cultured to recover the produced monoclonal antibody.
Eight milliliters of a 1 mg/m~ solution of FITC
(fluorescein isothiocyanate)-labelled anti-MYcoPlasma pneumonia monoclonal antibody (Gl-~6) in a 50 mM phosphate buffer (pH 7.0) were mixed with 92 m~ of a 50 mM phosphate buffer (pH 7.0) containing 500 mg of bovine serum albumin (BSA), 850 mg of sodium chloride, 4 mg of Evan's Blue, ancl 50 mg o sodium azide to prepare 100 mQ of an antibody solution. The solution was put in brown glass bottles in an amount of 1 m~ per bottle.
. ;~ . ' ' , -21~1~~
An antibody solution was prepared in the same manneras in Example 1, except for usiny no azo dye. The solution was put in brown glass bottles in an amount of 1 mQ per bottle.
Monoclonal antibody activity of a MYcoPlasma pneumonia diagnostic reagent comprising the FITc-labelled monoclonal antibody prepared in Example 1 or Comparative Example 1 was determined with time by enzyme-linked immunosorbent assay (ELISA) in the following manner.
Mycoplasma Pneumonia cells were immobilized on a 96-well microplate (Nunc) by physical adsorption followed by blocking with BSA. The test antibody solution was distributed to each well and incubated at 37C for 1 hour.
After washing the wells, horseradish peroxidase-labeled anti- -mouse IgG or IgM antibody solution was added to each well and incubated at 37C for 30 minutes. After washing the wells, an o-phenylenediamine solution was added to each well to effect color development, the reac~ion was t~rminated by adding sulfuric acid and the absorbance of the reaction mixture was measured. The antibody concentration was determined from the calibration curve which had been separately prepared. The relative activity of the antibody was calculated taking the initial activity as a standard ~100~. The results obtained are shown in Table 1 below.
:~ , . , .
,.
21~03 Relative Activity PreservationPreservation Comparative Time Conditions Example 1Example 1 initial stage~ - 100 100 3 months in refrig- 100 100 erator at room tem- 90 70 perature*~
6 months in refrig- 90 90 erator*
at room tem- 75 25 perature**
Note: *: 4 to 8C
**: 20 to 25C
The following 4 antibody solutions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
Solution A: A 0.1 mg/mQ solution of an anti-MYcoplasma pneumonia monoclonal antibody (C2H5-C10, IgG) in physiological saline buffered with a 1/15 M phosphoric acid (pH 7.2).
Solution B: Solu~ion A having fur-ther dissolved therein BSA to a concentration of 5 mg/mQ.
Solution C: Solution B having further dissolved therein Congo Red to a concentration of 0.004 mg/mQ.
Solu-tion D: Solution B haviny further dissolved therein Congo Red to a concentration of 0.04 my/mQ.
2 ~ 3 Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 7 days. The residual antibody activity was measured by ELISA in the same manner as in Test Example 1. The results obtained are shown in Table 2 below.
Residual Solution ACtiVitY `~
(%) -:
EXAMPLE 3 ~: -The following 4 solutions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
olution A: A 0.1 m~/mQ solution of an anti-Mvcoplasma pneumonia monoclonal antibody (3-19-11, IgM) in physiological saline bu~fered with a 1/15 M phosphoric acid (pH 7.2).
olution B: Solution A having further dissolved therein BSA to a concentration of 5 mg/mQ.
olution C: Solution B having further dissolved therein Evan's Blue to a concentration of 0.004 mg/mQ.
2 ~ 0 3 olution D: Solution B having further dissolved therein Evan's Blue to a concentration of 0.04 mg/mQ.
Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 7 days. The residual antibody activity was measured by ELISA in the same manner as in Test Example 1. The results obtained are shown in Table 3 below.
Residual So]ution Activitv (96) The following 4 solu~ions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
Solution A: A 0.1 mg/mQ solution of an anti-Candida albicans protease monoclonal antibody (IgG) in physiological saline buffered with a 1/15 M phosphoric acid (pH 7.2).
Solution B: Solution A having further dissolved therein BSA to a concentration of 5 mg/mQ.
~ . :
2 ~
Solution C: Solution B having further dissolved therein Evan's Blue to a concentration of 0.004 mg/m~.
Solution D: Solution B having further dissolved therein ~-Evan's Blue to a concentration of 0.04 mg/mQ.
Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 3 days. The residual antibody activity was measured by ELISA in the same manner as in Test ExaMple 1. The results obtained are shown in Table 4 below.
Residual Solution Activi~y (%) While the in~ention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
~ 11 --.
: - .
~: .
.; ~ '
FIELD OF THE INVENTION
This invention relates to a stable antibody or labelled antibody solution and to a method for stabilizing an antibody or a labelled antibody.
BACKGROUND OF THE INVENTION
A number of diagnostic reagents using an antibody or a labelled an~ibody have recently been developed. In particular, a monoclonal antibody has been ste~dily ex~ending its utility in the field of diagnosis and therapeutic drugs hecause of its high reaction specificity.
Many of antibodies, especially monoclonal antibodies composed of a single protein, have a unique character, which has made it difficult to obtain a stable solution thereof.
Similarly to general enzyme proteins, methods of preserving antibodies include freezing, lyophilization and ammonium sulfate fractionation followed by suspension. However, these methods not only involve complicated steps not easy to carry out but require much labor for preparing an anti~ody solution from the preserved state on use.
Studies have thus been given to a method for preserving an antibody in the form of a solution. Proposals so far made for obtainin~ an antibody solution include a method of adding albumin (WO 92/01808 corresponding to EP--A-0 539 584) and a method of adding hydrolyzed egg albumin ~P-A-61~76423 corresponding to U.S. Paten-t 4,650,772 and EP~A~0 - ~-... :
,;, . .
170 983, the term ~'JP-A~' as used herein means an "unexamined published Japanese patent application"). These methods, however, are still unsatisfactory for preparing a stabilized antibody solution.
SUMI~ARY OF THE INVENTION
An object of th0 present invention is to provide a stable antibody solution.
Another object of the present invention is to provide a method for stabilizing an antibody.
As a result of extensive investigations, the present inventors have found that addition of a specific azo dye which has no stabilizing effect when used alone to an antibody solution containing albumin surprisingly brings about a marked improvement in antibody stability. The present invention has been completed based on this finding.
The present invention provides an antibody solution containing (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure.
The present invention also provides a method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody.
, :
... ~ .:.:
~ .
2 ~ 0 3 DETAILED DESCRIPTION OF THE INVENTION
The antibody which can be stabilized according to the present invention is not particularly limited in kind and concentration, etc., and may be selected appropriately depending on the use. If desired, the antibody selected may be labelled with, for examp7e, fluorescent substance, such as fluorescein or rhodamine; biotin; enzyme, such as peroxidase or alkaline phosphatase; radioactive substance, such as l25I
and the like.
The concentration of the antibody in the antibody solution of the present invention varies depending on the type of the antibody. For example, anti-MYcoPlasma Pneumonia monoclonal antibody Gl-E6 is contained in a concentration ranging from 10 to 200 ~g/mQ.
Albumin which can be us~d in the present invention includes bovine serum albumin, human albumin~ ovalbumin, lactalbumin, etc. Since monoclonal antibodies are composed of a single protein unlike a polyclonal antibody obtained from antiserum, they mostly have a sp2cific character and their stability varies depending on the kind. Accordingly, where the antibody to be stabilized is a monoclonal antibody, it is desirable to select one or more kinds of albumin species according to the kind of the antibody. The albumin is used in an amount effective to stabilize the antibody, preferably in a concentration ranging from 1 to 20 mg/mQ in the antibody solution, though varying depending on the kind of the antibody.
- .
`",-:
.,. ~ , j,:. . .~ : . ~
6~3 The azo dye containing naphthalenesulfonic acid in its structure includes, for example, Direct Green 1, Direct Green 6, Direct Green 59, Direct Black 4, Direct BlacX 22, Direct Black 38, Direct Blue 1, Direct Blue 6, Direct Blue 53 (Evan's Blue), Direct Red 2, Direct Red 28 (Congo Red), and Direct Red 79, etc.
Although these azo dyes make no contribution to stabilization of an antibody when used alone, they exhibit a high stabilizing activity when combined with albumin. While varying depending on the kind of the antibody used, the azo dye is added in an amount effective to enhance antibody-stabilizing ability of albumin, preferably in a concentration ranging from 1 to 100 ~q/mQ in the antibody solution.
Usually, one kind of azo dyes would be sufficient. If necessary, two or more kinds of azo dyes may be used at an appropriate ratio.
A buffer solution having a neutral pH value can be used as a solution to which the components are added.
Examples of the buffer solutions include physiological saline, phosphate buffer, Tris-hydrochloride buffer, HEPES
buffer and the like. The pH value of the antibody solution is adjusted to 5 to 9, preferably 6 to 8, though it varies depending on the type of the antibody.
If desired, the antibody solution according to the present invention may urther contain antiseptics or preservatives, such as sodium azide and the like.
:: :
2~
The antibody solution of the present invention can be prepared by mixing the above-mentioned essential components (1) to (3) in a usual manner. For example, an antibody is dissolved in a solution containing 1 to 20 mg/mQ of albumin, and an azo dye is then added thereto in a concentration of from 1 to 100 ~g/m~. It is also possible to mix an antibody solution with a separatel~ prepared solution containing the o~her components. The order of addition of components (1) to (3) is not xestricted. Thereafter, if desired, an antiseptic, a preservative or any other additives may be added and dissolved oxygen may be removed from the solution.
The resulting solution may be then put into a light-shielding container to provide a final product of a stable antibody solution.
The antibody solution of the present invention can be used as a diagnosing reagent, a reagent for detecting various antigens and the like.
According to the present invention, an antibody can be preserved stably in the form of a solu~ion which is convenient for use.
The present invention will now be illustrated in greater detail with reference to Examples and Test Examples, but the present invention should not be construed as beiny limited thereto. Monoclonal antibodies used in Examples are ~s follows.
-2 i ~ 3 Gl-E6:
Disclosed in JP-A-63-184064.
C2H5-C10 and 3-19-11:
Separately prepared by the same method as disclosed in JP-A-63-184064.
Anti-Candida albicans protease monoclonal antibody (IqG):
A mouse (Balb/c, female) ~as immunized with acidic protease of a pathogenic yeast, Candida albicans (see F.
Macdnald and F.C. Odds, J. Med. Microbiol., Vol. 13, pp. 423-435 (1980)3 together with complete Freund's adjuvant. After a booster shot, spleen cells of the animal and myeloma cells (X63-Ag8.6.5.3) were fused together with the aid of polyethylene glycol according to the process described in JP-A-~3-184064. The resulting monoclonal antibody-producing hybridoma was cultured to recover the produced monoclonal antibody.
Eight milliliters of a 1 mg/m~ solution of FITC
(fluorescein isothiocyanate)-labelled anti-MYcoPlasma pneumonia monoclonal antibody (Gl-~6) in a 50 mM phosphate buffer (pH 7.0) were mixed with 92 m~ of a 50 mM phosphate buffer (pH 7.0) containing 500 mg of bovine serum albumin (BSA), 850 mg of sodium chloride, 4 mg of Evan's Blue, ancl 50 mg o sodium azide to prepare 100 mQ of an antibody solution. The solution was put in brown glass bottles in an amount of 1 m~ per bottle.
. ;~ . ' ' , -21~1~~
An antibody solution was prepared in the same manneras in Example 1, except for usiny no azo dye. The solution was put in brown glass bottles in an amount of 1 mQ per bottle.
Monoclonal antibody activity of a MYcoPlasma pneumonia diagnostic reagent comprising the FITc-labelled monoclonal antibody prepared in Example 1 or Comparative Example 1 was determined with time by enzyme-linked immunosorbent assay (ELISA) in the following manner.
Mycoplasma Pneumonia cells were immobilized on a 96-well microplate (Nunc) by physical adsorption followed by blocking with BSA. The test antibody solution was distributed to each well and incubated at 37C for 1 hour.
After washing the wells, horseradish peroxidase-labeled anti- -mouse IgG or IgM antibody solution was added to each well and incubated at 37C for 30 minutes. After washing the wells, an o-phenylenediamine solution was added to each well to effect color development, the reac~ion was t~rminated by adding sulfuric acid and the absorbance of the reaction mixture was measured. The antibody concentration was determined from the calibration curve which had been separately prepared. The relative activity of the antibody was calculated taking the initial activity as a standard ~100~. The results obtained are shown in Table 1 below.
:~ , . , .
,.
21~03 Relative Activity PreservationPreservation Comparative Time Conditions Example 1Example 1 initial stage~ - 100 100 3 months in refrig- 100 100 erator at room tem- 90 70 perature*~
6 months in refrig- 90 90 erator*
at room tem- 75 25 perature**
Note: *: 4 to 8C
**: 20 to 25C
The following 4 antibody solutions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
Solution A: A 0.1 mg/mQ solution of an anti-MYcoplasma pneumonia monoclonal antibody (C2H5-C10, IgG) in physiological saline buffered with a 1/15 M phosphoric acid (pH 7.2).
Solution B: Solu~ion A having fur-ther dissolved therein BSA to a concentration of 5 mg/mQ.
Solution C: Solution B having further dissolved therein Congo Red to a concentration of 0.004 mg/mQ.
Solu-tion D: Solution B haviny further dissolved therein Congo Red to a concentration of 0.04 my/mQ.
2 ~ 3 Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 7 days. The residual antibody activity was measured by ELISA in the same manner as in Test Example 1. The results obtained are shown in Table 2 below.
Residual Solution ACtiVitY `~
(%) -:
EXAMPLE 3 ~: -The following 4 solutions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
olution A: A 0.1 m~/mQ solution of an anti-Mvcoplasma pneumonia monoclonal antibody (3-19-11, IgM) in physiological saline bu~fered with a 1/15 M phosphoric acid (pH 7.2).
olution B: Solution A having further dissolved therein BSA to a concentration of 5 mg/mQ.
olution C: Solution B having further dissolved therein Evan's Blue to a concentration of 0.004 mg/mQ.
2 ~ 0 3 olution D: Solution B having further dissolved therein Evan's Blue to a concentration of 0.04 mg/mQ.
Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 7 days. The residual antibody activity was measured by ELISA in the same manner as in Test Example 1. The results obtained are shown in Table 3 below.
Residual So]ution Activitv (96) The following 4 solu~ions were prepared, and the effect of stabilizing a monoclonal antibody under severe conditions was examined.
Solution A: A 0.1 mg/mQ solution of an anti-Candida albicans protease monoclonal antibody (IgG) in physiological saline buffered with a 1/15 M phosphoric acid (pH 7.2).
Solution B: Solution A having further dissolved therein BSA to a concentration of 5 mg/mQ.
~ . :
2 ~
Solution C: Solution B having further dissolved therein Evan's Blue to a concentration of 0.004 mg/m~.
Solution D: Solution B having further dissolved therein ~-Evan's Blue to a concentration of 0.04 mg/mQ.
Each of solutions A to D was sealed into a brown glass bottle and allowed to stand at 50C for 3 days. The residual antibody activity was measured by ELISA in the same manner as in Test ExaMple 1. The results obtained are shown in Table 4 below.
Residual Solution Activi~y (%) While the in~ention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
~ 11 --.
: - .
~: .
.; ~ '
Claims (8)
1. An antibody solution comprising (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure.
2. The antibody solution as claimed in Claim 1, wherein said azo dye is selected from Direct Green 1, Direct Green 6, Direct Green 59, Direct Black 4, Direct Black 22, Direct Black 38, Direct Blue 1, Direct Blue 6, Direct Blue 53 (Evan's Blue), Direct Red 2, Direct Red 28 (Congo Red), and Direct Red 79.
3. The antibody solution as claimed in Claim 1, wherein said azo dye is contained in a concentration of from 1 to 100 µg/m?.
4. The antibody solution as claimed in Claim 1, wherein said albumin is contained in a concentration of from 1 to 20 mg/m?.
5. The antibody solution as claimed in Claim 1, wherein said antibody or a labelled antibody is a monoclonal antibody or a labelled monoclonal antibody.
6. A method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody.
7. The method as claimed in Claim 6, wherein said antibody or a labelled antibody is a monoclonal antibody or a labelled monoclonal antibody.
8. The use of an azo dye containing naphthalenesulfonic acid in its structure in an antibody solution comprising an antibody or a labelled antibody and albumin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4337478A JP2553445B2 (en) | 1992-12-17 | 1992-12-17 | Antibody stabilization method |
| JPHEI.4-337478 | 1992-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2111603A1 true CA2111603A1 (en) | 1994-06-18 |
Family
ID=18309028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002111603A Abandoned CA2111603A1 (en) | 1992-12-17 | 1993-12-16 | Stable antibody solution and stabilization of antibody |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5602234A (en) |
| EP (1) | EP0602601B1 (en) |
| JP (1) | JP2553445B2 (en) |
| KR (1) | KR100263398B1 (en) |
| CA (1) | CA2111603A1 (en) |
| DE (1) | DE69325634T2 (en) |
| TW (1) | TW348217B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069697A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Colorimetrically assessing peptide characteristics |
| WO2006079091A1 (en) * | 2005-01-24 | 2006-07-27 | Mallinckrodt Inc. | Methods of providing long-term stability to biocompatible optical dyes and bodily fluids |
| JP4965302B2 (en) * | 2007-03-26 | 2012-07-04 | 東洋紡績株式会社 | Antibody stabilization methods |
| US8003314B2 (en) | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
| JP6643761B2 (en) * | 2014-02-24 | 2020-02-12 | 国立大学法人名古屋大学 | Protective agent for protein cryopreservation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1180957A (en) * | 1967-12-13 | 1970-02-11 | Sterling Winthrop Group Ltd | Improvements in or relating to Immunological Reagents for Diagnostic Techniques. |
| DE2364792A1 (en) * | 1973-01-15 | 1974-07-18 | South African Inventions | Gamma-Globulin purification - by precipitating impurities with uncharged polymers at pH 4-5 |
| JPS56145222A (en) * | 1980-04-28 | 1981-11-11 | Toshiyuki Hamaoka | Improved antibody and its preparation |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4748018A (en) * | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| US4650772A (en) * | 1984-08-09 | 1987-03-17 | Abbott Laboratories | Monoclonal antibody stabilization |
| JPS62289523A (en) * | 1986-06-09 | 1987-12-16 | Green Cross Corp:The | Heat treatment of immunoglobulin for intravenous administration |
| WO1992001808A1 (en) * | 1990-07-18 | 1992-02-06 | Dojin Iyaku-Kako Co., Ltd. | Reagent for diagnosing mycoplasma pneumoniae |
| JPH04173799A (en) * | 1990-11-05 | 1992-06-22 | Sanyo Chem Ind Ltd | Aqueous solution of prolactin |
-
1992
- 1992-12-17 JP JP4337478A patent/JP2553445B2/en not_active Expired - Lifetime
-
1993
- 1993-12-14 DE DE69325634T patent/DE69325634T2/en not_active Expired - Fee Related
- 1993-12-14 EP EP93120142A patent/EP0602601B1/en not_active Expired - Lifetime
- 1993-12-16 TW TW082110685A patent/TW348217B/en active
- 1993-12-16 CA CA002111603A patent/CA2111603A1/en not_active Abandoned
- 1993-12-16 KR KR1019930027983A patent/KR100263398B1/en not_active IP Right Cessation
-
1995
- 1995-02-13 US US08/387,375 patent/US5602234A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0602601A3 (en) | 1995-05-24 |
| US5602234A (en) | 1997-02-11 |
| TW348217B (en) | 1998-12-21 |
| DE69325634T2 (en) | 1999-12-09 |
| JP2553445B2 (en) | 1996-11-13 |
| KR940013537A (en) | 1994-07-15 |
| EP0602601B1 (en) | 1999-07-14 |
| KR100263398B1 (en) | 2000-08-01 |
| DE69325634D1 (en) | 1999-08-19 |
| EP0602601A2 (en) | 1994-06-22 |
| JPH06186230A (en) | 1994-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| White et al. | The isolation and characterization of plasminogen activators (urokinase) from human urine | |
| CN102080066A (en) | Method for detecting T-2 toxin and special reagent kit thereof | |
| Kovàcs et al. | Immunolocalization of the multi‐sarco/endoplasmic reticulum Ca2+ ATPase system in human platelets | |
| US5602234A (en) | Stable antibody solution and method for preparing same | |
| Guesdon et al. | An immunoenzymatic method for measuring low concentrations of antigens by single radial diffusion | |
| WO1986002364A1 (en) | Monoclonal antibodies and their use | |
| US4767843A (en) | Monoclonal antibody to cardiac myosin heavy chain | |
| Zhou et al. | Development of a novel antibody probe useful for domoic acid detection | |
| US3992516A (en) | Direct fluorescent antibody composition and method for P. Pneumocystis carinii | |
| CN103558386B (en) | The method of ELISA detection fusion albumen rMBP NAP | |
| JP3154724B2 (en) | Methods for detecting monoclonal antibodies, hybridomas and diarrheal shellfish poisons specific to diarrheal shellfish toxins | |
| Roelcke et al. | Studies on the specificities of two IgM lambda cold agglutinins | |
| Skerritt et al. | Effects of solid phase and antigen solvent on the binding and immunoassay of water-insoluble flour proteins | |
| Martinez et al. | Antigenic relationships of fractionated western diamondback rattlesnake (Crotalus atrox) hemorrhagic toxins and other rattlesnake venoms as indicated by monoclonal antibodies | |
| US6767709B1 (en) | Immunoassay of human medullasin and diagnosis of multiple sclerosis using the same | |
| US4900664A (en) | Reagent for detection and measurement of acetaldehyde-protein condensates in a fluid, together with its preparation and method of use | |
| US20060057134A1 (en) | Antibody against antibacterial peptide and utiliazation thereof | |
| US5055405A (en) | Hybridoma cell line and monoclonal antibodies to Treponema species T. denticola JD-1 and Treponema 10A | |
| WO1986002365A1 (en) | Monoclonal antibodies and their use | |
| KR920008367B1 (en) | Hybridoma for progesterone | |
| US5008199A (en) | Hybridoma cell line and monoclonal antibodies to Treponema denticola ATCC 33520 | |
| US5192662A (en) | Anti-ganglioside GD1 A monoclonal antibody MZ, MZ-producing cells and MZ-containing reagent | |
| JP3576184B2 (en) | Diarrheal shellfish toxin-specific monoclonal antibody, hybridoma and diarrheal shellfish toxin detection method | |
| EP0186371A2 (en) | Monoclonal antibodies specific to antigens of Hepatitis B virus | |
| Puszkin et al. | Brain clathrin: A study of its properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |